Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β

Alzheimer's and Dementia

Volumn 13, Issue 9, 2017, Pages 1004-1012

  Mormino, Elizabeth C ^a   Papp, Kathryn V ^a   Rentz, Dorene M ^a   Donohue, Michael C ^b   Amariglio, Rebecca ^a   Quiroz, Yakeel T ^a   Chhatwal, Jasmeer ^a   Marshall, Gad A ^a   Donovan, Nancy ^a   Jackson, Jonathan ^a   Gatchel, Jennifer R ^a   Hanseeuw, Bernard J ^a   Schultz, Aaron P ^a   Aisen, Paul S ^b   Johnson, Keith A ^a   Sperling, Reisa A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Amyloid PET; Cognitive composite; Longitudinal cognitive decline; Preclinical Alzheimer's disease; Secondary prevention

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; APOLIPOPROTEIN E; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING; COGNITION ASSESSMENT; COHORT ANALYSIS; DEMENTIA ASSESSMENT; DIGIT SYMBOL SUBSTITUTION TEST; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE; PREVENTION STUDY; PRIORITY JOURNAL; RECALL; SECONDARY PREVENTION; SURVIVAL ANALYSIS; WECHSLER ADULT INTELLIGENCE SCALE; ASYMPTOMATIC DISEASE; COGNITIVE DEFECT; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; GENETICS; METABOLISM; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEINS E; ASYMPTOMATIC DISEASES; COGNITIVE DYSFUNCTION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; THIAZOLES;

EID: 85016063957     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.01.018     Document Type: Article

References (42)

1. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
2. Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7 (2011), 280–292.
3. Doraiswamy, P.M., Sperling, R.A., Coleman, R.E., Johnson, K.A., Reiman, E.M., Davis, M.D., et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 79 (2012), 1636–1644.
4. Landau, S.M., Mintun, M.A., Joshi, A.D., Koeppe, R.A., Petersen, R.C., Aisen, P.S., et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 72 (2012), 578–586.
5. Lim, Y.Y., Maruff, P., Pietrzak, R.H., Ames, D., Ellis, K.A., Harrington, K., et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 137 (2013), 221–231.
6. Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Ward, A., Huijbers, W., et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82 (2014), 1760–1767.
7. Petersen, R.C., Wiste, H.J., Weigand, S.D., Rocca, W.A., Roberts, R.O., Mielke, M.M., et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol 73 (2016), 85–92.
8. Snitz, B.E., Weissfeld, L.A., Lopez, O.L., Kuller, L.H., Saxton, J., Singhabahu, D.M., et al. Cognitive trajectories associated with beta-amyloid deposition in the oldest-old without dementia. Neurology 80 (2013), 1378–1384.
9. Mills, S.M., Mallmann, J., Santacruz, A.M., Fuqua, A., Carril, M., Aisen, P.S., et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 169 (2013), 737–743.
10. Reiman, E.M., Langbaum, J.B., Fleisher, A.S., Caselli, R.J., Chen, K., Ayutyanont, N., et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26 Suppl 3 (2011), 321–329.
11. Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med, 6, 2014, 228fs13.
12. Kozauer, N., Katz, R., Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 368 (2013), 1169–1171.
13. Clark, L.R., Racine, A.M., Koscik, R.L., Okonkwo, O.C., Engelman, C.D., Carlsson, C.M., et al. Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement 12 (2016), 805–814.
14. Storandt, M., Mintun, M.A., Head, D., Morris, J.C., Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 66 (2009), 1476–1481.
15. Langbaum, J.B., Hendrix, S.B., Ayutyanont, N., Chen, K., Fleisher, A.S., Shah, R.C., et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement 10 (2014), 666–674.
16. Lim, Y.Y., Snyder, P.J., Pietrzak, R.H., Ukiqi, A., Villemagne, V.L., Ames, D., et al. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: introducing the Z-scores of attention, verbal fluency, and episodic memory for nondemented older adults composite score. Alzheimers Dement (Amst) 2 (2016), 19–26.
17. Donohue, M.C., Sperling, R.A., Salmon, D.P., Rentz, D.M., Raman, R., Thomas, R.G., et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71 (2014), 961–970.
18. Kluger, A., Ferris, S.H., Golomb, J., Mittelman, M.S., Reisberg, B., Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol 12 (1999), 168–179.
19. Teng, E.L., Chui, H.C., The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 48 (1987), 314–318.
20. Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., et al. Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol 79 (2016), 110–119.
21. Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71 (2014), 1379–1385.
22. Wechsler, D., Wechsler Memory Scale-Revised. 1987, The Psychological Corporation, San Antonio.
23. Wechsler, D., WAIS-R Manual: Wechsler Adult Intelligence Scale-Revised. 1981, The Psychological Corporation, San Antonio.
24. Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
25. Grober, E., Merling, A., Heimlich, T., Lipton, R.B., Free and cued selective reminding and selective reminding in the elderly. J Clin Exp Neuropsychol 19 (1997), 643–654.
26. Di Stefano, F., Epelbaum, S., Coley, N., Cantet, C., Ousset, P.J., Hampel, H., et al. Prediction of Alzheimer's disease dementia: data from the GuidAge Prevention Trial. J Alzheimers Dis 48 (2015), 793–804.
27. Grober, E., Buschke, H., Genuine memory deficits in dementia. Dev Neuropsychol 3 (1987), 13–36.
28. Grober, E., Sanders, A.E., Hall, C., Lipton, R.B., Free and cued selective reminding identifies very mild dementia in primary care. Alzheimer Dis Assoc Disord 24 (2010), 284–290.
29. Sarazin, M., Berr, C., De Rotrou, J., Fabrigoule, C., Pasquier, F., Legrain, S., et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 69 (2007), 1859–1867.
30. Wagner, M., Wolf, S., Reischies, F.M., Daerr, M., Wolfsgruber, S., Jessen, F., et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 78 (2012), 379–386.
31. Morris, J.C., The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993), 2412–2414.
32. Roe, C.M., Fagan, A.M., Grant, E.A., Hassenstab, J., Moulder, K.L., Maue Dreyfus, D., et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80 (2013), 1784–1791.
33. Derby, C.A., Burns, L.C., Wang, C., Katz, M.J., Zimmerman, M.E., L'Italien, G., et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology 80 (2013), 1307–1314.
34. Elias, M.F., Beiser, A., Wolf, P.A., Au, R., White, R.F., D'Agostino, R.B., The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol 57 (2000), 808–813.
35. Grober, E., Hall, C.B., Lipton, R.B., Zonderman, A.B., Resnick, S.M., Kawas, C., Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 14 (2008), 266–278.
36. Bateman, R.J., Benzinger, T.L., Berry, S., Clifford, D.B., Duggan, C., Fagan, A.M., et al. The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model. Alzheimers Dement 13 (2017), 8–19.
37. Reiman, E.M., Langbaum, J.B., Tariot, P.N., Lopera, F., Bateman, R.J., Morris, J.C., et al. CAP—advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12 (2016), 56–61.
38. Papp, K.V., Mormino, E.C., Amariglio, R.E., Munro, C., Dagley, A., Schultz, A.P., et al. Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. Neuropsychology 30 (2015), 624–630.
39. Lim, Y.Y., Villemagne, V.L., Laws, S.M., Pietrzak, R.H., Ames, D., Fowler, C., et al. Performance on the Cogstate Brief battery is related to amyloid levels and hippocampal volume in very mild dementia. J Mol Neurosci 60 (2016), 362–370.
40. Rentz, D.M., Dekhtyar, M., Sherman, J., Burnham, S., Blacker, D., Aghjayan, S.L., et al. The feasibility of At-Home iPad Cognitive Testing for use in clinical trials. J Prev Alzheimers Dis 3 (2016), 8–12.
41. Burnham, S.C., Bourgeat, P., Dore, V., Savage, G., Brown, B., Laws, S., et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurol 15 (2016), 1044–1053.
42. Soldan, A., Pettigrew, C., Cai, Q., Wang, M.C., Moghekar, A.R., O'Brien, R.J., et al. Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol 73 (2016), 698–705.